ERBB2 and breast carcinoma: In this section, the clinical implication of those genetic and molecular factors on the choice of therapy for HER2-positive breast cancers are further discussed, with emphasis being placed on novel agents and combination therapies that are being investigated in clinical trials (Tables 2, 3).